JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

Guangzhou JOYO Pharma

Status and phase

Not yet enrolling

Phase 3

Conditions

Non Small Cell Lung Cancer

Treatments

Drug: JYP0322 tablets

Drug: Cross-over to JYP0322

Drug: Pemetrexed injection

Study type

Interventional

Funder types

Industry

Identifiers

NCT07154368

JYP0322M302

Details and patient eligibility

About

The primary purpose of the study was to compare progression-free survival of JYP0322 vs. platinum-based doublet chemotherapy in patients previously treated with ROS1-TKIs. Patients in the chemotherapy arm are given the option to switch to JYP0322 after BICR confirmed progressive disease (PD), while also have the choice to pursue with other drugs after discussing with their physicians.

Full description

This is a phase III, open label, randomized study assessing JYP0322 (150 mg, orally, tid) versus platinum-based doublet chemotherapy in subjects with confirmed diagnosis of ROS1 fusion positive NSCLC, who have progressed following prior therapy with one or two approved ROS1 Tyrosine Kinase Inhibitor (ROS1-TKI) agents and whose tumors harbors a ROS1 fusion positive. Subjects must agree to provide a biopsy for central confirmation of ROS1 fusion status. A total of 207 patients will be randomly assigned in a 2:1 ratio to receive oral JYP0322 (at a dose of 150mg tid) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus carboplatin (target area under the curve 5 [AUC5]) every 3 weeks for up to six cycles. Patients without disease progression after four cycles of platinu

Enrollment

207 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Key Inclusion Criteria
- Subjects with histologically or cytologically documented NSCLC.
- Locally advanced or metastatic ROS1 fusion positive NSCLC.
- Prior one or two ROS1-TKI(s) Treatment.
- World Health Organization (WHO) performance status 0-1.
- Life expectancy of at least 3 months.
- At least one measurable lesion according to RECISIT 1.1.

Exclusion criteria

Key Exclusion Criteria:
- Current participation in another therapeutic clinical trial.
- Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.
- A history of severe allergies, or a history of severe allergy, hypersensitivity or other hypersensitivity to any active or inactive ingredient of the study drug.
- All acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade more than 1.
- Any investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
- Known active infe